Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Sun Pharmaceutical Industries
Start SIPSun Pharmaceutical Industries F&O
Sun Pharmaceutical Industries Investment Rating
-
Master Rating:
-
Sun Pharm.Industries has an operating revenue of Rs. 43,885.68 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 21% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its key moving averages, around 2% and 2% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 2% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 55 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|
Oper Rev Qtr Cr | 5,801 | 4,550 | 5,285 | 4,862 | 3,988 |
Operating Expenses Qtr Cr | 3,588 | 3,646 | 3,622 | 3,483 | 3,007 |
Operating Profit Qtr Cr | 2,361 | 999 | 1,663 | 1,450 | 1,000 |
Depreciation Qtr Cr | 412 | 430 | 384 | 375 | 354 |
Interest Qtr Cr | 161 | 131 | 93 | 87 | 91 |
Tax Qtr Cr | -9 | 19 | 15 | 25 | 486 |
Net Profit Qtr Cr | -1,021 | 487 | 1,213 | 1,012 | -1,286 |
Sun Pharmaceutical Industries Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹964.36
- 50 Day
- ₹969.72
- 100 Day
- ₹975.27
- 200 Day
- ₹961.28
- 20 Day
- ₹955.12
- 50 Day
- ₹973.16
- 100 Day
- ₹986.46
- 200 Day
- ₹975.9
Sun Pharmaceutical Industries Resistance and Support
Resistance | |
---|---|
First Resistance | ₹993.77 |
Second Resistance | ₹999.84 |
Third Resistance | ₹1009.22 |
RSI | 64.1 |
MFI | 67 |
MACD Single Line | -4.36 |
MACD | 2.71 |
Support | |
---|---|
First Resistance | ₹978.32 |
Second Resistance | ₹968.94 |
Third Resistance | ₹962.87 |
Sun Pharmaceutical Industries Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 3,776,557 | 299,292,142 | 79.25 |
Week | 4,223,042 | 270,021,293 | 63.94 |
1 Month | 2,946,813 | 194,018,171 | 65.84 |
6 Month | 2,386,589 | 148,589,022 | 62.26 |
Sun Pharmaceutical Industries Result Highlights
Sun Pharmaceutical Industries Synopsis
NSE-Medical-Generic Drugs
Sun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 20812.14 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2023. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.Market Cap | 239,838 |
Sales | 20,812 |
Shares in Float | 110.37 |
No of funds | 1064 |
Yield | 1.05 |
Book Value | 10.1 |
U/D Vol ratio | 0.7 |
LTDebt / Equity | 32 |
Alpha | 0.05 |
Beta | 0.47 |
Sun Pharmaceutical Industries
Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
---|---|---|---|---|
Promoters | 54.48% | 54.48% | 54.48% | 54.48% |
Mutual Funds | 12.91% | 12.46% | 12.22% | 11.84% |
Insurance Companies | 5.12% | 5.55% | 6.36% | 7.52% |
Foreign Portfolio Investors | 16.88% | 16.87% | 16% | 14.95% |
Financial Institutions/ Banks | 0.08% | 0.04% | 0.15% | 0.22% |
Individual Investors | 5.7% | 5.76% | 5.91% | 6.31% |
Others | 4.83% | 4.84% | 4.88% | 4.68% |
Sun Pharmaceutical Industries Management
Name | Designation |
---|---|
Mr. Israel Makov | Chairman, Non Ind & Non Exe Director |
Mr. Dilip S Shanghvi | Managing Director |
Mr. Sailesh T Desai | Whole Time Director |
Mr. Kalyanasundaram Subramanian | Whole Time Director |
Mr. Sudhir V Valia | Non Exe.Non Ind.Director |
Dr. Pawan Goenka | Non Exe. & Ind. Director |
Mr. Rama Bijapurkar | Non Exe. & Ind. Director |
Mr. Gautam Doshi | Ind. Non-Executive Director |
Sun Pharmaceutical Industries Forecast
Price Estimates
Sun Pharmaceutical Industries Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-05-26 | Audited Results & Final Dividend | |
2023-01-31 | Quarterly Results & Interim Dividend | |
2022-11-01 | Quarterly Results | |
2022-07-29 | Quarterly Results | |
2022-05-30 | Audited Results & Final Dividend |
Date | Purpose | Remarks |
---|---|---|
2023-02-08 | INTERIM | Rs.7.50 per share(750%)Interim Dividend |
2022-08-22 | FINAL | Rs.3.00 per share(300%)Final Dividend |
2022-02-10 | INTERIM | Rs.7.00 per share(700%)Interim Dividend |
2021-02-10 | INTERIM | Rs.5.50 per share(550%)Interim Dividend |
Sun Pharmaceutical Industries FAQs
What is Share Price of Sun Pharmaceutical Industries ?
Sun Pharmaceutical Industries share price is ₹999 As on 03 June, 2023 | 22:37
What is the Market Cap of Sun Pharmaceutical Industries ?
The Market Cap of Sun Pharmaceutical Industries is ₹239837.5 Cr As on 03 June, 2023 | 22:37
What is the P/E ratio of Sun Pharmaceutical Industries ?
The P/E ratio of Sun Pharmaceutical Industries is 28.3 As on 03 June, 2023 | 22:37
What is the PB ratio of Sun Pharmaceutical Industries ?
The PB ratio of Sun Pharmaceutical Industries is 4 As on 03 June, 2023 | 22:37
What is the future of Sun Pharmaceutical Industries (Sun Pharma)?
Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD
Who is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma)?
Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).
What is the ROE of Sun Pharmaceutical Industries (Sun Pharma)?
The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.
Is Sun Pharmaceutical Industries (Sun Pharma) Debt to Equity Ratio?
Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.
What is the PE ratio of Sun Pharmaceutical Industries (Sun Pharma)?
The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.